JP5883458B2 - ポリ硫酸化多糖類を用いる骨髄浮腫（ｅｄｅｍａ（ｏｅｄｅｍａ））の治療 - Google Patents

ポリ硫酸化多糖類を用いる骨髄浮腫（ｅｄｅｍａ（ｏｅｄｅｍａ））の治療 Download PDF

Info

Publication number
JP5883458B2
JP5883458B2 JP2013552065A JP2013552065A JP5883458B2 JP 5883458 B2 JP5883458 B2 JP 5883458B2 JP 2013552065 A JP2013552065 A JP 2013552065A JP 2013552065 A JP2013552065 A JP 2013552065A JP 5883458 B2 JP5883458 B2 JP 5883458B2
Authority
JP
Japan
Prior art keywords
pentosan polysulfate
polysulfate
molecular weight
composition
weight heparin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2013552065A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014504613A (ja
JP2014504613A5 (enExample
Inventor
ゴーシュ，ピーター
Original Assignee
パラダイム ヘルス サイエンシズ プロプライエタリー リミテッド
パラダイム ヘルス サイエンシズ プロプライエタリー リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2011900325A external-priority patent/AU2011900325A0/en
Application filed by パラダイム ヘルス サイエンシズ プロプライエタリー リミテッド, パラダイム ヘルス サイエンシズ プロプライエタリー リミテッド filed Critical パラダイム ヘルス サイエンシズ プロプライエタリー リミテッド
Publication of JP2014504613A publication Critical patent/JP2014504613A/ja
Publication of JP2014504613A5 publication Critical patent/JP2014504613A5/ja
Application granted granted Critical
Publication of JP5883458B2 publication Critical patent/JP5883458B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2013552065A 2011-02-02 2012-02-02 ポリ硫酸化多糖類を用いる骨髄浮腫（ｅｄｅｍａ（ｏｅｄｅｍａ））の治療 Active JP5883458B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2011900325 2011-02-02
AU2011900325A AU2011900325A0 (en) 2011-02-02 Treatment of bone marrow edema (oedema) with polysulfated polysaccharides
PCT/AU2012/000091 WO2012103588A1 (en) 2011-02-02 2012-02-02 Treatment of bone marrow edema (oedema) with polysulfated polysaccharides

Publications (3)

Publication Number Publication Date
JP2014504613A JP2014504613A (ja) 2014-02-24
JP2014504613A5 JP2014504613A5 (enExample) 2015-03-19
JP5883458B2 true JP5883458B2 (ja) 2016-03-15

Family

ID=46602012

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013552065A Active JP5883458B2 (ja) 2011-02-02 2012-02-02 ポリ硫酸化多糖類を用いる骨髄浮腫（ｅｄｅｍａ（ｏｅｄｅｍａ））の治療

Country Status (15)

Country Link
US (6) US9101650B2 (enExample)
EP (1) EP2670412B1 (enExample)
JP (1) JP5883458B2 (enExample)
KR (1) KR101840079B1 (enExample)
CN (1) CN103415293B (enExample)
AU (1) AU2012212398B2 (enExample)
CA (1) CA2826166C (enExample)
DK (1) DK2670412T3 (enExample)
ES (1) ES2664611T3 (enExample)
MY (1) MY164728A (enExample)
NO (1) NO2670412T3 (enExample)
PT (1) PT2670412T (enExample)
SG (1) SG192238A1 (enExample)
TW (1) TWI520740B (enExample)
WO (1) WO2012103588A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014339000B2 (en) * 2013-10-22 2017-05-18 Cell Receptor AG Sulfated polysaccharides for use in the treatment of cancer
EP3661524A4 (en) * 2017-08-04 2021-05-05 Paradigm Biopharmaceuticals Limited TREATMENT OF BONE MARROW DISEASES WITH POLYSULFATED POLYSACCHARIDES
CA3089077A1 (en) 2018-02-16 2019-08-22 Proteobioactives Pty Limited Methods and compositions for the treatment of pain and/or inflammation
EP3758717A4 (en) * 2018-02-28 2021-11-24 Paradigm Biopharmaceuticals Limited TREATMENT OF POST-OPERATIVE JOINT PAIN WITH POLYSULFATED POLYSACCHARIDES
FI3863647T3 (fi) * 2018-10-10 2024-03-01 Paradigm Biopharmaceuticals Ltd Pahanlaatuisen luustokivun hoitaminen pentosaanipolysulfaatilla

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5668116A (en) 1987-03-19 1997-09-16 Anthropharm Pty. Limited Anti-inflammatory compounds and compositions
US6593310B1 (en) 2000-11-21 2003-07-15 Arthropharm Pty. Ltd. Treatment of osteoporosis
US6564083B2 (en) * 2000-12-18 2003-05-13 Hoffmann-La Roche Inc. Bone marrow edema as predictive of susceptibility to developing progressive osteoarthritis
DE10225551A1 (de) * 2002-06-06 2003-12-24 Schering Ag Verwendung von oral verfügbaren Prostacyclinderivaten für die Herstellung eines Arzneimittels zur Behandlung von Krankheiten, die mit Knochenmarködemen assoziiert sind
KR101995016B1 (ko) * 2007-12-04 2019-06-28 프로테오바이오엑티브스 피티와이 엘티디 전구 세포의 보호 및 그의 분화 조절

Also Published As

Publication number Publication date
AU2012212398A1 (en) 2013-09-19
WO2012103588A1 (en) 2012-08-09
US20140024614A1 (en) 2014-01-23
DK2670412T3 (en) 2018-03-12
CA2826166A1 (en) 2012-08-09
JP2014504613A (ja) 2014-02-24
SG192238A1 (en) 2013-09-30
NO2670412T3 (enExample) 2018-06-02
CN103415293A (zh) 2013-11-27
ES2664611T3 (es) 2018-04-20
AU2012212398B2 (en) 2014-06-05
KR20140012655A (ko) 2014-02-03
US20240156858A1 (en) 2024-05-16
US10610542B2 (en) 2020-04-07
TW201309307A (zh) 2013-03-01
CA2826166C (en) 2017-05-09
US9861657B2 (en) 2018-01-09
US11406660B2 (en) 2022-08-09
US20220362284A1 (en) 2022-11-17
US20150297633A1 (en) 2015-10-22
TWI520740B (zh) 2016-02-11
KR101840079B1 (ko) 2018-03-19
US20210015849A1 (en) 2021-01-21
EP2670412A4 (en) 2015-07-08
EP2670412A1 (en) 2013-12-11
US20180021369A1 (en) 2018-01-25
EP2670412B1 (en) 2018-01-03
US9101650B2 (en) 2015-08-11
MY164728A (en) 2018-01-30
PT2670412T (pt) 2018-03-20
CN103415293B (zh) 2016-08-10

Similar Documents

Publication Publication Date Title
US20240156858A1 (en) Treatment of Bone Marrow Edema (Oedema) With Polysulfated Polysaccharides
KR20090051100A (ko) Ｆｇｆ-18 로 연골 질환의 치료
Santos et al. Cartilage lesions and ankle osteoarthrosis: review of the literature and treatment algorithm
Herman et al. Complications of tibial eminence and diaphyseal fractures in children: prevention and treatment.
van Roermund et al. Joint distraction in the treatment of ankle osteoarthritis
KR20200062182A (ko) 다황화된 다당류를 이용한 골수 병리의 치료
JP7391858B2 (ja) ポリ硫酸化多糖類を用いた術後関節痛の処置
Tabaracci et al. Osteochondritis dissecans of the femoral condylus treated with ozone and hyaluronic acid
Sheeraz Prevention and Postoperative Care
Augie Sarcouncil Journal of Medicine and Surgery
陳柏旭 et al. The improvement of pain symptoms and activities of daily living in people with knee osteoarthritis after intra-articular hyaluronic acid injection
Montaser Arthroscopic treatment of traumatic anterior bony ankle impingement
Strauss et al. Identifying and managing ankle fractures in older patients
Slater et al. A Review of Distraction Arthroplasty Vs Ankle Arthrodesis Vs Ankle Replacement. J Regen Biol Med. 2021; 4 (1) 1-28

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150130

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150130

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20151013

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151228

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20160126

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160205

R150 Certificate of patent or registration of utility model

Ref document number: 5883458

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250